ACT is a personalized strategy that involves infusing an ex vivo-expanded pool of endogenous tumor-reactive T cells, such as tumor-infiltrating lymphocyte (TIL) (9) and endogenous T-cell (10), or artificially producing tumor-reactive T cells (11), such as engineered T cells expressing transgenic T-cell receptors (TCRs) or chimeric antigen receptors (CARs) (12). Here, CARS1 is linked to neoplasm.